Search

Author/Creator Truman, Matt

1. A multi‐centre, single‐arm, open‐label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R‐ITP1000 study). (11th July 2014)

Authors:
Tran, Huyen; Brighton, Tim; Grigg, Andrew; McRae, Simon; Dixon, Joanna; Thurley, Daniel; Gandhi, Maher K.; Truman, Matt; Marlton, Paula; Catalano, John
Journal:
British journal of haematology
Issue:
Volume 167:Number 2(2014:Oct.)
Page Start:
243
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. Issue 1 (31st May 2022)

Authors:
McDonald, Stephen; Yiu, Sean; Su, Li; Gordon, Caroline; Truman, Matt; Lisk, Laura; Solomons, Neil; Bruce, Ian N
Other Names:
author non-byline.; Bruce Ian N author non-byline.; Payne Katherine author non-byline.; Lunt Mark author non-byline.; Peek Niels author non-byline.; Geifman Nophar author non-byline.; Gavan Sean author non-byline.; Armitt Gillian author non-byline.; Doherty Patrick author non-byline.; Prattley J...
Journal:
Lupus science & medicine
Issue:
Volume 9:Issue 1(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. (August 2016)

Authors:
Mok, Tony; Ladrera, Guia; Srimuninnimit, Vichien; Sriuranpong, Virote; Yu, Chong-Jen; Thongprasert, Sumitra; Sandoval-Tan, Jennifer; Lee, Jin Soo; Fuerte, Fatima; Shames, David S.; Klughammer, Barbara; Truman, Matt; Perez-Moreno, Pablo; Wu, Yi-Long
Journal:
Lung cancer
Issue:
Volume 98(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. (August 2016)

Authors:
Mok, Tony; Ladrera, Guia; Srimuninnimit, Vichien; Sriuranpong, Virote; Yu, Chong-Jen; Thongprasert, Sumitra; Sandoval-Tan, Jennifer; Lee, Jin Soo; Fuerte, Fatima; Shames, David S.; Klughammer, Barbara; Truman, Matt; Perez-Moreno, Pablo; Wu, Yi-Long
Journal:
Lung cancer
Issue:
Volume 98(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗